Prothionamide

{{Short description|Chemical compound}}

{{Short description|Chemical compound}}

{{Use dmy dates|date=September 2025}}

{{Drugbox

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| Verifiedfields = changed

| Verifiedfields = changed

| Watchedfields = changed

| Watchedfields = changed

| IUPAC_name = 2-propylpyridine-4-carbothioamide

| IUPAC_name = 2-propylpyridine-4-carbothioamide

| image = Protionamide.svg

| image = Protionamide.svg

| alt =

| image2 = Prothionamide 3D ball.png

| image2 = Prothionamide 3D ball.png

| alt2 =

<!–Clinical data–>

<!–Clinical data–>

| Drugs.com = {{drugs.com|international|prothionamide}}

| Drugs.com = {{drugs.com|international|prothionamide}}

| pregnancy_AU = <!– A / B1 / B2 / B3 / C / D / X –>

| pregnancy_AU = <!– A / B1 / B2 / B3 / C / D / X –>

| pregnancy_US = <!– A / B / C / D / X –>

| pregnancy_category =

| pregnancy_category =

| routes_of_administration =

| ATC_prefix = J04

| ATC_suffix = AD01

| legal_AU = <!– Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 –>

| legal_AU = <!– Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 –>

| legal_CA = <!– / Schedule I, II, III, IV, V, VI, VII, VIII –>

| legal_CA = <!– / Schedule I, II, III, IV, V, VI, VII, VIII –>

| legal_US = <!– OTC / Rx-only / Schedule I, II, III, IV, V –>

| legal_US = <!– OTC / Rx-only / Schedule I, II, III, IV, V –>

| legal_status =

| legal_status =

| routes_of_administration =

<!–Pharmacokinetic data–>

<!–Pharmacokinetic data–>

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 14222-60-7

| CAS_number = 14222-60-7

| ATC_prefix = J04

| ATC_suffix = AD01

| PubChem = 666418

| PubChem = 666418

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

”’Protionamide”’ (or ”’prothionamide”’) is a drug used in the treatment of [[tuberculosis]] and [[leprosy]].<ref name=”pmid17227913″>{{cite journal |vauthors=Wang F, Langley R, Gulten G, etal |title=Mechanism of thioamide drug action against tuberculosis and leprosy |journal=J. Exp. Med. |volume=204 |issue=1 |pages=73–8 |date=January 2007 |pmid=17227913 |pmc=2118422 |doi=10.1084/jem.20062100 |url=http://www.jem.org/cgi/pmidlookup?view=long&pmid=17227913}}</ref><ref name=”pmid16525107″>{{cite journal |vauthors=Fajardo TT, Guinto RS, Cellona RV, Abalos RM, Dela Cruz EC, Gelber RH |title=A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy |journal=Am. J. Trop. Med. Hyg. |volume=74 |issue=3 |pages=457–61 |date=March 2006 |doi=10.4269/ajtmh.2006.74.457 |pmid=16525107 |s2cid=21415032 |url=http://www.ajtmh.org/cgi/pmidlookup?view=long&pmid=16525107|doi-access=free |url-access=subscription }}</ref>

”’Protionamide”’ (or ”’prothionamide”’) is a drug used in the treatment of [[tuberculosis]] and [[leprosy]].<ref name=”pmid17227913″>{{cite journal |vauthors=Wang F, Langley R, Gulten G, etal |title=Mechanism of thioamide drug action against tuberculosis and leprosy |journal=J. Exp. Med. |volume=204 |issue=1 |pages=73–8 |date=January 2007 |pmid=17227913 |pmc=2118422 |doi=10.1084/jem.20062100 |url=http://www.jem.org/cgi/pmidlookup?view=long&pmid=17227913}}</ref><ref name=”pmid16525107″>{{cite journal |vauthors=Fajardo TT, Guinto RS, Cellona RV, Abalos RM, Dela Cruz EC, Gelber RH |title=A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy |journal=Am. J. Trop. Med. Hyg. |volume=74 |issue=3 |pages=457–61 |date=March 2006 |doi=10.4269/ajtmh.2006.74.457 |pmid=16525107 |s2cid=21415032 |url=http://www.ajtmh.org/cgi/pmidlookup?view=long&pmid=16525107|doi-access=free |url-access=subscription }}</ref>

Protionamide is a therapeutic alternative on the [[WHO Model List of Essential Medicines|World Health Organization’s List of Essential Medicines]].<ref name=”WHO24th”>{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list | year = 2025 | hdl = 10665/382243 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | hdl-access=free }}</ref>

==References==

==References==

{{Antimycobacterials}}

{{Antimycobacterials}}

{{Portal bar | Medicine}}

{{Authority control}}

[[Category:Disubstituted pyridines]]

[[Category:Disubstituted pyridines]]

[[Category:Thioamides]]

[[Category:Thioamides]]

[[Category:Anti-tuberculosis drugs]]

[[Category:Anti-tuberculosis drugs]]

[[Category:World Health Organization essential medicines]]

{{antiinfective-drug-stub}}

{{antiinfective-drug-stub}}